Literature DB >> 17879106

[Aneurysmal subarachnoid hemorrhage. Significance and complications].

A S Sarrafzadeh1, U Kaisers, W Boemke.   

Abstract

Despite substantial improvement in the management of patients with aneurysmal subarachnoid hemorrhage (SAH), including early aneurysm occlusion by endovascular techniques and surgical procedures, a significant percentage of patients with SAH still experience serious sequelae of neurological or cognitive deficits as a result of primary hemorrhage and/or secondary brain damage. Available neuromonitoring methods for early recognition of ischemia include, among others, measurement of brain tissue O(2) partial pressure, brain metabolism with microdialysis and monitoring of regional blood flow. The triple-H therapy (arterial hypertension, hypervolemia and hemodilution) is the treatment of choice of a symptomatic vasospasm and leads to an enduring recession of ischemic symptoms, if initiated early after the onset of a vasospasm-linked ischemic neurological deficit. Further promising therapy approaches are the administration of highly selective ET(A) receptor antagonists and intracisternal administration of vasodilators in depot form. This review summarizes the major neurological and non-neurological complications following aneurysm occlusion. Possible neuromonitoring techniques to improve diagnosis and therapy for treatment of symptomatic vasospasm as well as extracranial complications are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17879106     DOI: 10.1007/s00101-007-1244-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  72 in total

1.  Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage.

Authors:  Richard S Veyna; Donald Seyfried; Don G Burke; Chris Zimmerman; Mark Mlynarek; Victoria Nichols; Anna Marrocco; Ajith J Thomas; Panayiotis D Mitsias; Ghiaus M Malik
Journal:  J Neurosurg       Date:  2002-03       Impact factor: 5.115

2.  Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations.

Authors:  Jens P Dreier; Johannes Woitzik; Martin Fabricius; Robin Bhatia; Sebastian Major; Chistoph Drenckhahn; Thomas-Nicolas Lehmann; Asita Sarrafzadeh; Lisette Willumsen; Jed A Hartings; Oliver W Sakowitz; Jörg H Seemann; Anja Thieme; Martin Lauritzen; Anthony J Strong
Journal:  Brain       Date:  2006-10-25       Impact factor: 13.501

3.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

4.  Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients.

Authors:  K L Holloway; T Barnes; S Choi; R Bullock; L F Marshall; H M Eisenberg; J A Jane; J D Ward; H F Young; A Marmarou
Journal:  J Neurosurg       Date:  1996-09       Impact factor: 5.115

5.  Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.

Authors:  Peter Vajkoczy; Bernhard Meyer; Stefan Weidauer; Andreas Raabe; Claudius Thome; Florian Ringel; Volker Breu; Peter Schmiedek
Journal:  J Neurosurg       Date:  2005-07       Impact factor: 5.115

6.  Pulmonary function and radiographic abnormalities related to neurological outcome after aneurysmal subarachnoid hemorrhage.

Authors:  A Gruber; A Reinprecht; H Görzer; P Fridrich; T Czech; U M Illievich; B Richling
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

7.  Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage.

Authors:  Paul Klimo; John R W Kestle; Joel D MacDonald; Richard H Schmidt
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

8.  Acute focal neurological deficits in aneurysmal subarachnoid hemorrhage: relation of clinical course, CT findings, and metabolite abnormalities monitored with bedside microdialysis.

Authors:  Asita Sarrafzadeh; Daniel Haux; Oliver Sakowitz; Goetz Benndorf; Harry Herzog; Ingeborg Kuechler; Andreas Unterberg
Journal:  Stroke       Date:  2003-05-15       Impact factor: 7.914

9.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

10.  Brain tissue oxygen (PtiO2): a clinical comparison of two monitoring devices.

Authors:  M Jaeger; M Soehle; J Meixensberger
Journal:  Acta Neurochir Suppl       Date:  2005
View more
  2 in total

1.  Long-term impact of perfusion CT data after subarachnoid hemorrhage.

Authors:  Christian Mathys; Daniel Martens; Dorothea C Reichelt; Julian Caspers; Joel Aissa; Rebecca May; Daniel Hänggi; Gerald Antoch; Bernd Turowski
Journal:  Neuroradiology       Date:  2013-09-13       Impact factor: 2.804

Review 2.  [Aneurysmal subarachnoid hemorrhage].

Authors:  P Kellner; D Stoevesandt; J Soukup; M Bucher; C Raspé
Journal:  Anaesthesist       Date:  2012-09       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.